Search - tctmd.com

Displaying 61 - 80 of 141

Sort: Relevancy | Date

Cangrelor is ready for prime time

Presentation JIM 2018

Cangrelor is ready for prime time

Presenter: Dominick J. Angiolillo

February 23, 2018

Switching Antiplatelet Therapy: New International Consensus

Podcast TCTMD Talking Points

Switching Antiplatelet Therapy: New International Consensus

January 24, 2018

De-escalating DAPT to a Clopidogrel-Based Strategy After PCI for ACS Gets Boost in TOPIC-VASP

News Daily News

De-escalating DAPT to a Clopidogrel-Based Strategy After PCI for ACS Gets Boost in TOPIC-VASP

Yael L. Maxwell

January 04, 2018

Rationale and Studies of P2Y12 Inhibitor Monotherapy

Presentation TCT 2017

Rationale and Studies of P2Y12 Inhibitor Monotherapy

Presenter: Dominick J. Angiolillo, Marco Valgimigli, Roxana Mehran

October 30, 2017

Utility of Genotyping and Platelet Function Testing to Guide Antiplatelet Therapy: 2017 Assessment

Presentation TCT 2017

Utility of Genotyping and Platelet Function Testing to Guide Antiplatelet Therapy: 2017 Assessment

Presenter: Dominick J. Angiolillo, Marco Valgimigli, Thomas Engstroem

October 30, 2017

Switching to and From Cangrelor: When and How?

Presentation TCT 2017

Switching to and From Cangrelor: When and How?

Presenter: Dominick J. Angiolillo, Marco Valgimigli

October 30, 2017

Switching Between Oral P2Y12 Receptor Inhibitors: When and How?

Presentation TCT 2017

Switching Between Oral P2Y12 Receptor Inhibitors: When and How?

Presenter: Dominick J. Angiolillo, Marco Valgimigli, Matthew J. Price

October 30, 2017

Crushing and Chewing Oral P2Y12 Receptor Inhibitors: Pharmacodynamic and Clinical Impact

Presentation TCT 2017

Crushing and Chewing Oral P2Y12 Receptor Inhibitors: Pharmacodynamic and Clinical Impact

Presenter: Dominick J. Angiolillo, Marco Valgimigli, Fabiana Rollini

October 30, 2017

Impact of Race and Sex on Platelet Reactivity and Clinical Implications

Presentation TCT 2017

Impact of Race and Sex on Platelet Reactivity and Clinical Implications

Presenter: Dominick J. Angiolillo, Marco Valgimigli, Ron Waksman

October 30, 2017

Help for Clinicians Whose Patients Need to Switch P2Y12 Inhibitors

News Conference News TCT 2017

Help for Clinicians Whose Patients Need to Switch P2Y12 Inhibitors

October 30, 2017

Interventional Pharmacology: A Guideline-based Review

Presentation TCT 2017

Interventional Pharmacology: A Guideline-based Review

Presenter: Jose de Ribamar Costa Jr, Jose L. Leiva-Pons, Dominick J. Angiolillo

October 29, 2017

DAPT Can Be Safely De-Escalated Post-PCI Based on Platelet Function Testing

News Conference News ESC 2017

DAPT Can Be Safely De-Escalated Post-PCI Based on Platelet Function Testing

September 07, 2017

ADAPT-DES at 2 Years Offers Insights Into Provider Strategies and Aspirin Monotherapy Beyond 1 Year

News Daily News

ADAPT-DES at 2 Years Offers Insights Into Provider Strategies and Aspirin Monotherapy Beyond 1 Year

Yael L. Maxwell

August 07, 2017

Triple Therapy Not Being Widely Used in A-fib Patients Undergoing PCI

News Daily News

Triple Therapy Not Being Widely Used in A-fib Patients Undergoing PCI

May 23, 2017

The ARTE of Antiplatelet Therapy After TAVR: Bleeding Greater with Clopidogrel Plus Aspirin vs Aspirin Alone

News Conference News EuroPCR 2017

The ARTE of Antiplatelet Therapy After TAVR: Bleeding Greater with Clopidogrel Plus Aspirin vs Aspirin Alone

Yael L. Maxwell

May 17, 2017

The Long and Short of It: DAPT Duration Choice After Stenting Gets Help From New Score

News Daily News

The Long and Short of It: DAPT Duration Choice After Stenting Gets Help From New Score

March 10, 2017

Intravenous P2Y12 Receptor Inhibitors: Now We Can Do It

Presentation JIM 2017

Intravenous P2Y12 Receptor Inhibitors: Now We Can Do It

Presenter: Dominick J. Angiolillo

February 10, 2017

News Daily News

Tricky Population of Patients With A-fib Undergoing PCI Tackled in New Consensus Document

November 29, 2016

Intravenous P2Y12 Receptor Inhibitors Transitioning to a Potent Oral Anti-platelet Agent if PCI Is Performed Is Optimal Treatment in NSTE-ACS

Presentation TCT 2016

Intravenous P2Y12 Receptor Inhibitors Transitioning to a Potent Oral Anti-platelet Agent if PCI Is Performed Is Optimal Treatment in NSTE-ACS

Presenter: Roxana Mehran, Ferdinando Varbella, Dominick J. Angiolillo

November 01, 2016

General Overview and Highlights of the North American Consensus Document on Anticoagulation in the Atrial Fibrillation Patient With ACS or PCI

Presentation TCT 2016

General Overview and Highlights of the North American Consensus Document on Anticoagulation in the Atrial Fibrillation Patient With ACS or PCI

Presenter: David P. Faxon, C. Michael Gibson, Dominick J. Angiolillo

November 01, 2016

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.